We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Accesso Technology Group Plc | LSE:ACSO | London | Ordinary Share | GB0001771426 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.94% | 536.00 | 531.00 | 536.00 | 536.00 | 531.00 | 535.00 | 28,939 | 16:25:32 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Cmp Integrated Sys Design | 139.73M | 10.06M | 0.2395 | 22.38 | 225.08M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/11/2018 11:49 | It is surprising the company haven't really come out and comment on the share price piece at least. Before that came out it was probably difficult to say no reason for drop. Now they can reference the piece and try to rebut it. Could be argued they should try and avoid a slanging match but equally long term holders getting creamed need protecting as well. Interesting that TT are getting even more aggressive even as it falls. Opposite of what should really be happening as the very easy gains have probably been made for now. | horndean eagle | |
12/11/2018 08:20 | Not negative, just realistic! Even the most hardened investor and supporter of a company has to take capital preservation measures at some point.Let's hope it doesn't come to that.spud | spud | |
12/11/2018 07:50 | Wednesday, accesso is holding a press event at the 2018 IAAPA Attractions Expo. If they have anything new product-wise up their sleeve, or they win another one of the industry awards, this week and this trade show is when we would hear about it. | 1001011 | |
12/11/2018 07:28 | that's very negative spud - unlike you. what has made you change your mind? | janeann | |
12/11/2018 07:25 | We are now just above the placing price of £16.20 on 13-Jul-17 relating to the purchase of TE2. | shanklin | |
11/11/2018 16:32 | The Market will need reassurance at some point regardless unless the Company is happy to have a run on the price. We’re seeing zero support from IIs atm and without it, this could very easily slip below £10. If that happens even I will have to re-evaluate my position here... spud | spud | |
11/11/2018 16:14 | If there is any bad business/trading news, the company would be obliged to rns it anyway. An absence of a statement can therefore be read as good news. There is also the risk that a ‘reassuring | aimingupward2 | |
11/11/2018 15:50 | Indeed - An increase from 0.7% to 0.86%. My guess is they'll continue to increase their Short position until the price is such that the Company is forced to issue a statement. A drop of 50% + within 4 week timeframe (below £15) should trigger that imo. spud | spud | |
11/11/2018 11:24 | As of 6th Nov, TT International had a short position of 0.86% hxxps://shorttracker | chasbas | |
10/11/2018 18:36 | FWIW An analysis of the trading on Friday ' Data uses total of all deals made with no difference between buys or sells. If you assumes each dealt was either a discrete buy or sell divided by 2 to get number of shares changing hands. ' Deals Grouped by bands of shares traded ' Band___________Num Deals_____Value_____ by number of shares ' Up to 500 NMS______101______&p >500 <=1,500________27 >1,500 <=5,000______20__ >5,000 <=10,000_____13__ >10,000 <=50,000_____8___ Over 50,000__________2___ ==================== Total _____________171____ Cancelled___________ ' Roughly a quarter of the deals in the highest 4 bands accounted for some 98 % of the total value. Highest band with two entries has some 25% of total value. ' Private Investors normally trade around Normal market size NMS or 500. ' IMHO___Volatility of this thinly traded share was created by just a handful of large active traders. Append Above table show discrete deals but a number of probable day trades are noted. The most notable being a confident £1.1 million trade late in the day. Date/Time___________ 15:55:25 09-Nov-2018 1,650.00 GBX 70,297 1,159,900.50 16:08:37 09-Nov-2018 1,651.65 GBX 70,297 1,161,060.40 Thirteen minutes and enough gross to pay for a hospitality ticket to the All Blacks game at Twickenham. | togglebrush | |
10/11/2018 10:51 | 17%, 47%, 11%, or 4%... which number are you going to pick? Good luck. | skatersav | |
10/11/2018 10:36 | In the interims they state that stripping out the acquisitions: “ Underlying like for like growth, on a consistent IFRS 15 basis, was approximately 11%.” Why is that dishonest? | wjccghcc | |
10/11/2018 10:01 | My post was aimed at the claim of dishonest in the ShareProphets article. Let’s get things straight. Management made a massive brouhaha about their “47% underlying growth” at the recent results, but this “overlooked | skatersav | |
10/11/2018 09:56 | Wrong! The H1 revenue number is compared against the H1 2017 revenue number - this removes seasonality. | skatersav | |
10/11/2018 09:23 | Isnt the bigger point to take operational cash flow from the last 5 years, say that capex is excessive because of investment for growth, and therefore make adjustments to it (haircut by 50% is easy enough). Issue is that you take this normalised free cash flow number and the stock still looks expensive. And that's what determines business value. Do you really see investment going down over the next 5 years? Ive tried a DCF Also, lets not forget that this growth is not organic. Theyve bought a substantial chunk of it | dan_the_epic | |
10/11/2018 08:06 | Think you've nailed it itchy - Pretty much the way I view it. And although you could argue that I really don't really need any more stock, it's a function of a successful investor to accumulate more wealth as a reflection of his investment strategy and ultimate success.spud | spud | |
10/11/2018 06:18 | The hangman there's a blast from the past ...he was arguing this overvalued at 30p....8 or 9 years ago? | sonofbanjosinger | |
10/11/2018 00:39 | The fundamental oversight(/dishonest In the theme park industry, July, August, and Halloween (all in H2) are when the big cash rolls in and when off-season investments pay off. H1 growth, be it revenue or cash flow, is supposed to lag full-year growth expectations, by design, for an H2-heavy seasonal business. The off-season and low-season aren't meaningful predictors of peak season growth. | 1001011 | |
09/11/2018 23:31 | Accesso has created a portfolio of solutions that has gained widespread traction and has opened up huge opportunities in other areas that were originally not even target sectors. As a result, and to capitalise on the growth in these areas, Accesso (and quite rightly so), is investing heavily in its future growth. It's just the normal function of a company undergoing a period or rapid growth. If ever there was a buy and hold stock then Accesso is it. Unless you really understand the business and the management it's easy to adopt a 'traders mentality'. For me, the drop in the share price represents an unbelievable opportunity to add at levels I never expected to see again, especially with the low liquidity (which has largely exaggerated this drop in the share price). Building a large holding has always been difficult due to the low float and low liquidity. I have been and will continue to drip-buy on an ongoing basis. | itchycrack | |
09/11/2018 19:15 | I've read the Shareprophets article. They make some compelling points around free cash flow. Can they really turn off that spending tap? On a free cash flow basis, the stock is very weak, so the big question is what is normalised free cash flow and then value Accesso on a 4% free cash flow yield off that. At the moment, that answer is quite negative on my numbers | dan_the_epic | |
09/11/2018 19:15 | He was certainly here early days along with Glenn who sold at just over a quid to buy a load of property. I suppose I shouldn’t̵ | the big fella | |
09/11/2018 17:43 | Never did buy the percy 350k - Especially when he inadvertently let slip a comment about his boss when the shares were @ circa £8. Probably bought 3k’s worth, had a few pints and got carried away late night on the keyboard. Sceptical spud | spud | |
09/11/2018 15:01 | Just looking at ACSO's tweets and think this job in the "healthcare vertical" sounds quite interesting in terms of what ACSO are seeking to achieve. 401K, Medical Employment Type Full-Time Why Work Here? “Innovative technology company servicing clients in the attractions industry, awesome work culture, rapidly growing with generous benefits!” About Us accesso® is a worldwide software company delivering industry-leading virtual queuing, eCommerce, ticketing, and experience management solutions for a wide range of industries, including attractions, hospitality, healthcare, cultural, leisure and quick-service food. Our products and services already support some of the top venues in the world including a wide variety of paid admission operations in household name attractions, ranging from theme parks, water parks and zoos to cultural attractions, cruise ships and sporting events. Our innovative approach to driving revenue is a key differentiator of our proprietary and patented technology. We help our clients achieve their goals through our unsurpassed service, rapid-release software deployment and commitment to innovation. Everything we do helps our clients focus on what they do best - providing outstanding experiences for guests - while we provide technology that readily supports our clients’ efforts to drive revenue. We have focused intensely on fine tuning our process to ensure success for our clients and our company. Position Overview The Senior Product Manager for accesso's healthcare vertical is responsible for all product management related functions for CareReady. CareReady combines the software of TE2 with the wearable technology of accesso LoQueue. This role will work with other product teams to bring the CareReady MVP to market. The goal for the CareReady solution is to transform the patient experience by eliminating the communication gaps in a hospital setting, while assisting healthcare providers to undercover operational inefficiencies and opportunities to elevate their HCAHPS scores. The CareReady Senior Product Manager will meet with current and future customers, develop and own the backlog, prove out product market fit, and work closely with partners (internal and external) to develop the CareReady product roadmap, drive software releases, and support customer launches. The CareReady Senior Product Manager will use a dual-track agile product discovery process to rapidly introduce new capabilities. You will be working closely with other Product Management teams, Business Development, UX, and Engineering. Reports To: President, TE2 (interim) Location: Lake Mary, FL Travel: Up to 50% to internal and external meetings. Key Responsibilities and Deliverables Assess product opportunities within the healthcare space and validate decisions with clients and users. Define, test and prove what product and features are to be prioritized and built. Leverage tools and techniques that are customary for the product management function. Define MVP and new features, write user stories and acceptance criteria, define KPIs, set OKRs, own and prioritize backlog, and triage defects to iteratively deliver, launch, and measure the success of each release. Create and manage the product roadmap for CareReady, insuring your team is always working on the highest priority functionality. Identify opportunities for new features and develop business and product plans and success metrics to make the case for investment. Set quantifiable goals with customers to increase their HCAHPS scores. Work closely with cross-functional accesso stakeholders to understand current and future requirements for CareReady, while also understanding the market landscape of available solutions. Build trusted and valuable relationships, supported by great communication skills with the engineering, quality, and project management and scrum teams to ensure a successful and coordinated product development process, including working through development dependencies. Attend and present at customer meetings, internal company functions, and healthcare conferences to aid business development. Ensure product and services are aligned to customer needs. Ensure we communicate product releases through presentations and authoring of customer release notes and documentation in conjunction with technical writers. Support the scrum team in designing platform functionality, reviewing design documents and architecture, and participating in technical discussions. Conduct candidate interviews and help scale the healthcare vertical at accesso. Work with Business Development to: Create a comprehensive vision and annual sales strategy, focused on gross margin and profitability. Continually gather and analyze market data and industry trends within healthcare vertical. Present objective data for build vs. buy decisions relating to bringing CareReady to market. Develop a comprehensive understanding of the competitive landscape. Create and refine value messaging for the CareReady product. Experience & Requirements 7+ years of product management experience, with a minimum of 3 years of experience within the healthcare space. 4+ years of customer facing product and/or business development experience. BS Degree or equivalent work experience. Experience conducting product discovery testing. Experience establishing goals and metrics to measure effectiveness after releases; monitor & report on progress. Ability to analyze potential partner relationships. Strong team skills, both as a leader of a product team but also working across product teams to get the best results for the company. Ability to converse fluently engineers about technology as well as executives and customers about business needs and objectives. What We Offer Competitive salary based on experience The opportunity to earn an annual company discretionary bonus with the potential for stock options Generous Paid Time Off as well as paid Volunteer Time Off Health insurance plans, including employer-contributed HSA and employer-paid disability and life insurance. Matching 401K Unlimited access to Udemy for Business for continued learning and career development A flexible work schedule around our core business hours Other Considerations We are an E-Verify organization. Eligible candidates must be authorized to work in the US without requiring visa sponsorship. accesso is a drug free and smoke free company, meaning employees may not smoke or use illegal drugs while at work or away from work. This is a full-time position. No contractors please. If you are interested in joining a team who values Passion, Commitment, Teamwork, Innovation and Integrity and what we’ve described above is YOU, then apply today and let’s talk! accesso Technology Group, plc About accesso Technology Group, plc: accesso technology has been providing cutting edge queuing and ticketing solutions to major theme parks and attractions for over a decade. Our powerful and innovative solutions deliver breakthrough revenue generating technology for our clients around the world. Our products and services currently support some of the top attractions in the world including a wide variety of paid admission operations ranging from theme parks, water parks and zoos to cultural attractions and sporting events. Our innovative approach to driving revenue are key differentiators of our proprietary and patented technology. We help our clients achieve their goals through our unsurpassed service, rapid release software deployment and commitment to innovation. Everything we do helps our clients focus on what they do best, providing outstanding experiences for guests while we provide technology that readily supports our clients efforts to drive revenue. We have focused intensely on fine tuning our process to ensure success for our clients and, in turn, our company. Company website: Company address: 1025 Greenwood Blvd #500, Lake Mary, FL 32746 | shanklin | |
09/11/2018 12:27 | Morning Hangers. This was the one that well and truelly got away for me. 250k shares at under 10p nearly all sold before £1. Hey ho. | the big fella | |
09/11/2018 11:58 | Dear me,i'm no chartist but Just look at the chart.., looking like another big spike downwards, just hope this does not turn into another CRAW, but those unlucky shareholders, did get a couple of dividends, Morning BF, hope you are keeping well | mr hangman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions